2. Search Result
Search Result
Results for "

FAP1

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-164567
    SID 125240931

    		Others Cancer
    SID 125240931 is a fluorogen activating proteins (FAPs) modulator. SID 125240931 interferes with the binding between fluorogens and FAP .
    SID 125240931
  • HY-160289
    ARI-3144

    		FAP Cancer
    ARI-3144 is an excellent and specific substrate for fibroblast activation protein (FAP). ARI-3144 is usually coupled with the fluorophore 7-Amino-4-methylcoumarin (HY-D0027) (AMC) for detection and quantification of FAP .
    ARI-3144
  • HY-108944
    LYP-IN-1

    		SHP2 SHP1 Phosphatase Inflammation/Immunology
    LYP-IN-1 is a potent, selective and specific LYP inhibitor with a Ki and an IC50 of 110 nM and 0.259 μM, respectively. LYP-IN-1 also has selectivity for a large panel of PTPs, such as SHP1 (IC50=5 μM) and SHP2 (IC50=2.5 μM). LYP-IN-1 exhibits highly efficacious cellular activity in T- and mast cells. LYP-IN-1 can be used for the study of autoimmune disorders [1]. LYP-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    LYP-IN-1
  • HY-103323
    Fas C-Terminal Tripeptide

    		FAP Others
    Fas C-Terminal Tripeptide is a C-terminal tripeptide of Fas. Fas C-Terminal Tripeptide shows the inhibitory effect on Fas/FAP-1 binding [1].
    Fas C-Terminal Tripeptide
  • HY-RS11418
    PTPN13 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    PTPN13 Human Pre-designed siRNA Set A contains three designed siRNAs for PTPN13 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PTPN13 Human Pre-designed siRNA Set A
    PTPN13 Human Pre-designed siRNA Set A
  • HY-178028
    PRMT5-IN-53

    		Histone Methyltransferase Cancer
    PRMT5-IN-53 is a gut-restricted and orally active PRMT5 inhibitor with pIC50s of ≥ 9.7 against hPRMT5 and mPRMT5. PRMT5-IN-53 binds to the PRMT5:MEP50 complex with a KD of 11.3 pM. PRMT5-IN-53 effectively inhibits PRMT5 locally in the intestines of mice, significantly reducing the number and area of polyps, while avoiding systemic hematological toxicity (such as anemia, neutropenia). PRMT5-IN-53 can be used for the study of colorectal cancer especially for familial adenomatous polyposis (FAP) .
    PRMT5-IN-53

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: